Tuberculosis in renal transplant recipients: a Brazilian center registry.
Renal transplant recipients receiving immunosuppression show an increased risk for developing opportunistic infections, such as tuberculosis (TB). TB represents the major cause of morbidity and mortality in the world, mainly in underdeveloped countries. The aim of this study was to analyze the incidence of TB and its presentation among renal transplant recipients over 20 years.


METHODS
This retrospective analysis included medical records of renal transplant recipients from January 1984 to April 2007.


RESULTS
Among 1342 renal transplant recipients, 31 received treatment for TB due to clinical disease (n = 23) or prophylaxis (n = 8). The overall incidence of TB was 1.71%, which was diagnosed at 53 +/- 49 months posttransplantation. The indications for TB prophylaxis were a previous history of TB (n = 6) or direct contact with a TB carrier (n = 1). The most common clinical presentation was extrapulmonary (n = 13). The classical treatment was effective in 16 cases. However, 7 cases of resistant TB required ethambutol added to therapy. Adverse events of treatment included liver toxicity (n = 1) and peripheral neuropathy (n = 1). Three patients died due to TB-related complications. Graft loss was observed in 3 patients after cessation of TB treatment. None of the patients on prophylaxis developed clinical disease.


CONCLUSIONS
TB incidence was significantly greater among renal transplant recipients compared with the local population, with a higher incidence of extrapulmonary disease. TB prophylaxis in selected cases was effective, avoiding new infections.
Guida
J P S
JP
Division of Nephrology, Department of Medicine, School of Medical Sciences, State University of Campinas-DCM/FCM/UNICAMP, Campinas, Brazil.
Bignotto Rosane
D
D
Urbini-Santos
C
C
Alves-Filho
G
G
Ribeiro Resende
M
M
Mazzali
M
M
D000995:Antitubercular Agents / Q000627:therapeutic use*; D001706:Biopsy; D001938:Brazil / Q000453:epidemiology; D004977:Ethambutol / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D012008:Recurrence; D012042:Registries; D012189:Retrospective Studies; D014376:Tuberculosis / Q000453:epidemiology* / Q000473:pathology
D000995:Antitubercular Agents; D004977:Ethambutol